摘要
目的观察经皮局部注射神经生长因子对骨折愈合的影响。方法选取2014年1月至9月住院的84例骨折患者,根据随机数字表法将其分为对照组(口服三七片)和观察组(经皮局部注射神经生长因子),各42例,观察和比较两组临床疗效、骨折愈合时间、骨痂生长情况及不良反应发生情况。结果与对照组相比,观察组治愈率(50.00%比26.19%)及总有效率(97.62%比83.33%)明显升高(P<0.05),胫骨干骨折愈合时间[(10.0±1.5)周比(12.5±2.4)周]、肱骨干骨折愈合时间[(7.2±1.1)周比(8.4±1.5)周]、股骨干骨折愈合时间[(11.0±2.5)周比(13.5±3.0)周]均明显缩短(P<0.05);术后3周内,两组骨痂最大直径[(4.5±1.1)mm比(4.4±1.1)mm]比较,差异无统计学意义(P>0.05);而术后3周以后,观察组骨痂最大直径较对照组明显增大[(7.2±1.8)mm比(5.5±1.3)mm](P<0.05)。两组均未出现严重不良反应。结论局部注射神经生长因子能够促进骨折愈合,且不良反应少,具有较高安全性,值得临床推广。
Objective To investigate the effect of percutaneous local injection of nerve growth factor ( NGF ) on fracture healing. Methods 84 fracture patients in our hospital from January 2014 to September 2014 were randomized into the control group ( oral Sanqi Tablets ) and the observation group ( percutaneous local injection of NGF ) according to the random number method, 42 cases in each group. The clinical efficacy, fracture healing time, bone callus growth state and adverse reactions were observed and compared in the two groups. Results Compared with the control group, the cure rate and total effective rate in the observation group were significantly increased ( 50. 00% vs. 26. 19%, 97. 62% vs. 83. 33%, P 〈 0. 05 ); compared with the control group, the fracture healing times of tibial shaft, humeral shaft and femoral shaft in the observation group were obviously reduced ( 10. 0 ± 1. 5 vs. 12. 5 ± 2. 4, 7. 2 ± 1. 1 vs. 8. 4 ± 1. 5, 11. 0 ± 2. 5 vs. 13. 5 ± 3. 0, P 〈 0. 05 );the maximum diameter of bone callus within 3 weeks after operation in the two groups had no statistical difference ( 4. 5 ± 1. 1 vs. 4. 4 ± 1. 1, P 〉 0. 05 ) , however, compared with the control group, the maximum diameter of bone callus at postoperative 3 weeks in the observation group was significantly increased ( 7. 2 ± 1. 8 vs. 5. 5 ± 1. 3, P 〈 0. 05 ) . No serious adverse reactions appeared during the treatment period in the two groups. Conclusion The percutaneous local injection of NGF can significantly promote the fracture healing and has less adverse reactions with high treatment security, and is worthy of clinical promotion.
出处
《中国药业》
CAS
2015年第9期41-42,共2页
China Pharmaceuticals
关键词
神经生长因子
骨折
愈合
nerve growth factor
fracture
healing